Stockreport

Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors

Foghorn Therapeutics Inc.  (FHTX) 
PDF CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicin [Read more]